Eisai files biliary tract cancer drug tasurgratinib in Japan

Eisai files biliary tract cancer drug tasurgratinib in Japan

Source: 
Pharmaphorum
snippet: 

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion mutations.